JP2014506900A5 - - Google Patents

Download PDF

Info

Publication number
JP2014506900A5
JP2014506900A5 JP2013555798A JP2013555798A JP2014506900A5 JP 2014506900 A5 JP2014506900 A5 JP 2014506900A5 JP 2013555798 A JP2013555798 A JP 2013555798A JP 2013555798 A JP2013555798 A JP 2013555798A JP 2014506900 A5 JP2014506900 A5 JP 2014506900A5
Authority
JP
Japan
Prior art keywords
solution
tapentadol
criteria
hcl
result
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013555798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506900A (ja
JP6027549B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/000906 external-priority patent/WO2012119729A1/en
Publication of JP2014506900A publication Critical patent/JP2014506900A/ja
Publication of JP2014506900A5 publication Critical patent/JP2014506900A5/ja
Application granted granted Critical
Publication of JP6027549B2 publication Critical patent/JP6027549B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013555798A 2011-03-04 2012-03-02 タペンタドールを含む半固形の水性医薬組成物 Expired - Fee Related JP6027549B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161449329P 2011-03-04 2011-03-04
US61/449,329 2011-03-04
EP11003603.5 2011-05-03
EP11003603 2011-05-03
PCT/EP2012/000906 WO2012119729A1 (en) 2011-03-04 2012-03-02 Semisolid aqueous pharmaceutical composition containing tapentadol

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016200663A Division JP6259042B2 (ja) 2011-03-04 2016-10-12 タペンタドールを含む半固形の水性医薬組成物

Publications (3)

Publication Number Publication Date
JP2014506900A JP2014506900A (ja) 2014-03-20
JP2014506900A5 true JP2014506900A5 (OSRAM) 2016-09-01
JP6027549B2 JP6027549B2 (ja) 2016-11-16

Family

ID=44652117

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013555798A Expired - Fee Related JP6027549B2 (ja) 2011-03-04 2012-03-02 タペンタドールを含む半固形の水性医薬組成物
JP2016200663A Expired - Fee Related JP6259042B2 (ja) 2011-03-04 2016-10-12 タペンタドールを含む半固形の水性医薬組成物
JP2017228602A Expired - Fee Related JP6670283B2 (ja) 2011-03-04 2017-11-29 タペンタドールを含む半固形の水性医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016200663A Expired - Fee Related JP6259042B2 (ja) 2011-03-04 2016-10-12 タペンタドールを含む半固形の水性医薬組成物
JP2017228602A Expired - Fee Related JP6670283B2 (ja) 2011-03-04 2017-11-29 タペンタドールを含む半固形の水性医薬組成物

Country Status (24)

Country Link
US (3) US9446008B2 (OSRAM)
EP (3) EP3290029B1 (OSRAM)
JP (3) JP6027549B2 (OSRAM)
KR (2) KR102039320B1 (OSRAM)
CN (1) CN103501774A (OSRAM)
AU (2) AU2012224954C1 (OSRAM)
BR (1) BR112013022556A8 (OSRAM)
CA (1) CA2828637C (OSRAM)
CY (1) CY1119725T1 (OSRAM)
DK (1) DK2680834T3 (OSRAM)
EA (2) EA025194B1 (OSRAM)
ES (2) ES2910085T3 (OSRAM)
HR (1) HRP20171836T1 (OSRAM)
HU (1) HUE037491T2 (OSRAM)
IL (2) IL227826B (OSRAM)
LT (1) LT2680834T (OSRAM)
MX (2) MX344473B (OSRAM)
NO (1) NO2680834T3 (OSRAM)
PL (1) PL2680834T3 (OSRAM)
PT (2) PT2680834T (OSRAM)
RS (1) RS56692B1 (OSRAM)
SI (1) SI2680834T1 (OSRAM)
WO (1) WO2012119729A1 (OSRAM)
ZA (1) ZA201306480B (OSRAM)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012224954C1 (en) 2011-03-04 2017-04-06 Grünenthal GmbH Semisolid aqueous pharmaceutical composition containing tapentadol
EP3597182A1 (en) 2011-03-04 2020-01-22 Grünenthal GmbH Aqueous pharmaceutical formulation of tapentadol for oral administration
US9395306B2 (en) 2011-08-05 2016-07-19 Halliburton Energy Services, Inc. Methods for monitoring fluids within or produced from a subterranean formation during acidizing operations using opticoanalytical devices
US8997860B2 (en) 2011-08-05 2015-04-07 Halliburton Energy Services, Inc. Methods for monitoring the formation and transport of a fracturing fluid using opticoanalytical devices
US8619256B1 (en) 2012-09-14 2013-12-31 Halliburton Energy Services, Inc. Systems and methods for monitoring the properties of a fluid cement composition in a flow path
US20140076550A1 (en) 2012-09-14 2014-03-20 Halliburton Energy Services, Inc. Systems and Methods for Detecting Microannulus Formation and Remediation
US9228940B2 (en) 2012-09-14 2016-01-05 Halliburton Energy Services, Inc. Systems, methods, and apparatuses for in situ monitoring of cement fluid compositions and setting processes thereof
WO2015014980A1 (en) * 2013-08-02 2015-02-05 Ratiopharm Gmbh Composition comprising tapentadol in a dissolved form
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
CN107847471A (zh) * 2015-03-27 2018-03-27 格吕伦塔尔有限公司 他喷他多肠胃外给药的稳定制剂
PE20190908A1 (es) 2016-09-23 2019-06-26 Gruenenthal Chemie Formulacion estable para la administracion parenteral de tapentadol
US20210290536A1 (en) * 2018-07-24 2021-09-23 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Topical emulsion of an anticholinergic compound
US12447119B2 (en) 2019-03-18 2025-10-21 Sunstar Americas, Inc. Oral care composition

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775678A (en) * 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6183758B1 (en) * 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
AU2003225837B2 (en) 2002-03-15 2008-11-06 Forest Laboratories Holdings Limited NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
AU2003275329B2 (en) 2002-09-13 2008-04-03 Cydex Pharmaceuticals, Inc. Capsules containing aqueous fill compositions stabilized with derivatized cyclodextrin
US20040180915A1 (en) 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
WO2005112926A1 (en) 2004-05-17 2005-12-01 Pharmacofore, Inc. Compositions and methods for treating or preventing pain
ES2291780T3 (es) 2004-06-28 2008-03-01 Grunenthal Gmbh Formas cristalinas del clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)fenol.
BRPI0513300B1 (pt) 2004-07-01 2018-11-06 Gruenenthal Gmbh forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2- metil-lpropil)-fenol
AU2006239313A1 (en) 2005-04-28 2006-11-02 Najib Babul Methods and compositions for treating pain
TWI329334B (en) 2005-12-02 2010-08-21 Chung Shan Inst Of Science Manufacture method of electromagnetic interference layer for the plasma display panel
WO2007127158A2 (en) * 2006-04-25 2007-11-08 Croda, Inc Modification of percutaneous absorption of topically active materials
RU2465263C2 (ru) 2006-04-28 2012-10-27 Грюненталь Гмбх Фармацевтическая комбинация, включающая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и нестероидный противовоспалительный препарат
BRPI0710682B8 (pt) 2006-04-28 2021-05-25 Gruenenthal Gmbh combinação farmacêutica compreendendo 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol e paracetamol
PT2046726E (pt) 2006-07-24 2010-04-15 Janssen Pharmaceutica Nv Preparação da (2r,3r)-3-(3-metoxifenil)-n,n,2- trimetilpentanamina
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
PL2596784T3 (pl) * 2007-11-23 2017-06-30 Grünenthal GmbH Kompozycje tapentadolu
NZ586792A (en) 2008-01-25 2012-09-28 Gruenenthal Chemie Tamper resistant controlled release pharmaceutical tablets form having convex and concave surfaces
WO2010096045A1 (en) 2008-10-30 2010-08-26 Nectid, Inc. Novel and potent tapentadol dosage forms
US20100227921A1 (en) 2009-03-03 2010-09-09 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
WO2011083304A1 (en) * 2010-01-05 2011-07-14 Shire Llc Prodrugs of opioids and uses thereof
US8652511B2 (en) * 2010-03-30 2014-02-18 Phosphagenics Limited Transdermal delivery patch
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
US20120270848A1 (en) * 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
AU2012224954C1 (en) 2011-03-04 2017-04-06 Grünenthal GmbH Semisolid aqueous pharmaceutical composition containing tapentadol

Similar Documents

Publication Publication Date Title
JP2014506900A5 (OSRAM)
PE20140591A1 (es) Uso de una composicion que comprende un peptido antimicrobiano como un conservador de alimentos
RU2015141767A (ru) Композиции и способы для местной доставки простагландинов в подкожный жир
WO2014182566A3 (en) Preservation system for nutritional substances
WO2015085070A3 (en) Liquid-fertilized ready formulations of bifenthrin
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
WO2016142224A8 (en) Fungicidal mixtures comprising strobilurin-type fungicides
EP2792693A4 (en) FLUORATED COPOLYMER AND WATER- / OIL-REPELLENT MEDIUM WITH THIS COPOLYMER AS AN ACTIVE SUBSTANCE
WO2015171460A3 (en) Formulations of cyclophosphamide liquid concentrate
WO2015003082A3 (en) Volatile organic compound formulations having antimicrobial activity
MX2016000136A (es) Mezclas conservantes sinergicas.
WO2014169003A3 (en) Multi-functional composition for cosmetic formulations
WO2017069820A3 (en) Antimicrobial composition having efficacy against endospores
WO2012131117A8 (es) Utilización de antifúngicos naturales para prevenir la infección de lesiones, injertos y heridas de poda en plantas leñosas por hongos fitopatógenos
JP2017531030A5 (OSRAM)
MX2015011118A (es) Extracto de cafe que contiene acido protocatecuico y su uso en agroquimica contra patogenos de plantas.
RU2010146997A (ru) Фармацевтическая композиция, содержащая силденафил и/или алпростадил, миноксидил и/или эуфиллин, тестостерон и/или йохимбин и липосомы для местного применения
WO2016113752A3 (en) Liquid formulation of cabazitaxel
WO2015198265A3 (en) Disinfectant and antimicrobial compositions, in particular for the veterinary field
JP2020521060A5 (OSRAM)
PH12013502250A1 (en) Construction material preservative
WO2014137231A3 (en) Totarol extract formulations and uses thereof
JP2017537980A5 (OSRAM)
IN2014MU00284A (OSRAM)
JP2014159381A5 (OSRAM)